Iodopol (Sodium Iodide (131i))

Sodium Iodide (131I) is actively taken up by thyroid follicular cells via the sodium‑iodide symporter. Inside the gland, the isotope emits beta particles that destroy thyroid tissue, while gamma emissions can be captured for imaging. This dual action enables both treatment of disease and visualization of thyroid uptake.

The prescribed dose of Iodopol is individualized by the treating physician based on the specific indication, patient weight, thyroid uptake studies, and clinical goals. Dosage calculations follow established nuclear medicine protocols and are not standardized across all patients.

Iodopol is generally contraindicated in pregnancy because the radioactive iodine can affect the developing fetal thyroid. Breastfeeding should be discontinued before administration, as iodine can be secreted in milk and expose the infant to radiation. Consultation with a specialist is essential.

To order Iodopol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iodopol contains Sodium Iodide (131I), the same isotope used in other commercial radioactive iodine products. Differences may lie in formulation, regulatory approvals, and supply chain reliability. Clinically, the therapeutic and diagnostic effects are comparable when administered at equivalent activity levels.

Iodopol should be stored below 25 °C in its original packaging, protected from moisture and light. The product must be kept out of reach of unauthorized personnel, and any handling should follow radiopharmacy safety guidelines to prevent contamination or accidental exposure.

Iodopol is administered orally as a single dose under the supervision of a qualified nuclear medicine specialist. The patient typically ingests the preparation with water after fasting, and thyroid uptake is monitored using scintigraphy to assess distribution and therapeutic effect.

Serious risks include bone‑marrow suppression (e.g., aplastic anemia), severe radiation thyroiditis, pulmonary fibrosis, allergic reactions, and the potential for secondary malignancies due to radiation exposure. Patients should be monitored closely for hematologic changes and thyroid function after treatment.

Iodopol is contraindicated in pregnant women, nursing mothers, patients with severe renal impairment who cannot clear the isotope, and individuals with known hypersensitivity to iodine or radioactive substances. It should also be avoided in patients receiving high‑dose antithyroid medications that block iodine uptake.